Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

Background SARS-CoV-2 vaccines currently authorized for emergency use have been
highly successful in preventing infection and lessening disease severity. The vaccines …

Animal models in SARS-CoV-2 research | Nature Methods Skip to main content Thank you for
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …

Background The immune profile against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has dramatically diversified due to a complex combination of exposure to …

SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS)
antibodies that exist in diverse individuals as public antibody clones. We rationally selected …

Emerging variants of concern (VOCs) are threatening to limit the effectiveness of SARS-CoV-
2 monoclonal antibodies and vaccines currently used in clinical practice; broadly …

Abstract The SARS-CoV-2 B. 1.1. 529 variant (Omicron) contains 15 mutations on the
receptor-binding domain (RBD). How Omicron would evade RBD neutralizing antibodies …

The COVID‐19 pandemic has caused an unprecedented health crisis and economic burden
worldwide. Its etiological agent SARS‐CoV‐2, a new virus in the coronavirus family, has …